Download PDF
Thromb Haemost 2012; 108(01): 1-2
DOI: 10.1160/TH12-05-0312
Invited Editorial Focus
Schattauer GmbH

Propanolol and angiogenesis inhibition in hereditary haemorrhagic telangiectasia

Georg Breier
Institute of Pathology, University Clinic Dresden, Dresden, Germany
› Author Affiliations
Further Information

Publication History

Received: 14 May 2012

Accepted: 14 May 2012

Publication Date:
22 November 2017 (online)

    Permissions and Reprints

 

 

  • References

  • 1 Fernández-L A, Sanz-Rodriguez F, Blanco FJ. et al. Hereditary hemorrhagic telangiectasia, a vascular dysplasia affecting the TGF-beta signaling pathway. Clin Med Res 2006; 04: 66-78.
    CrossrefPubMedGoogle Scholar
  • 2 Shovlin CL. Hereditary haemorrhagic telangiectasia: pathophysiology, diagnosis and treatment. Blood Rev 2010; 24: 203-219.
    CrossrefPubMedGoogle Scholar
  • 3 Mahmoud M, Upton PD, Arthur HM. Angiogenesis regulation by TGFβ signalling: clues from an inherited vascular disease. Biochem Soc Trans 2011; 39: 1659-1666.
    CrossrefPubMedGoogle Scholar
  • 4 en Dijke P, Goumans MJ, Pardali E. Endoglin in angiogenesis and vascular diseases. Angiogenesis 2008; 11: 79-89.
    CrossrefPubMedGoogle Scholar
  • 5 Albiñana V, Bernabeu-Herrero ME, Zarrabeitia R. et al. Estrogen therapy for hereditary haemorrhagic telangiectasia (HHT): Effects of raloxifene, on Endoglin and ALK1 expression in endothelial cells. Thromb Haemost 2010; 103: 525-534.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 6 Bose P, Holter JL, Selby GB. Bevacizumab in hereditary hemorrhagic telangiectasia. N Engl J Med 2009; 360: 2143-2144.
    CrossrefPubMedGoogle Scholar
  • 7 Kabbinavar F, Hurwitz HI, Fehrenbacher L. et al. Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol 2003; 21: 60-65.
    CrossrefPubMedGoogle Scholar
  • 8 Lebrin F, Srun S, Raymond K. et al. Thalidomide stimulates vessel maturation and reduces epistaxis in individuals with hereditary hemorrhagic telangiectasia. Nat Med 2010; 16: 420-428.
    CrossrefPubMedGoogle Scholar
  • 9 Kurstin R. Using thalidomide in a patient with epithelioid leiomyosarcoma and Osler-Weber-Rendu disease. Oncology 2002; 16: 21-24.
    PubMedGoogle Scholar
  • 10 Albiñana V, Recio-Poveda L, Zarrabeitia R. et al. Propranolol as antiangiogenic candidate for the therapy of hereditary haemorrhagic telangiectasia. Thromb Haemost 2012; 108: 41-53.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 11 Lamy S, Lachambre M P, Lord-Dufour S. et al. Propranolol suppresses angiogenesis in vitro: inhibition of proliferation, migration, and differentiation of endothelial cells. Vascul Pharmacol 2010; 53: 200-208.
    CrossrefPubMedGoogle Scholar
  • 12 Léauté-Labrèze C, Dumas de la, Roque E, Hubiche T. et al. Propranolol for severe hemangiomas of infancy. N Engl J Med 2008; 358: 2649-2651.
    CrossrefPubMedGoogle Scholar
  • 13 Mazzone M, Dettori D, Leite de Oliveira R. et al. Heterozygous deficiency of PHD2 restores tumor oxygenation and inhibits metastasis via endothelial normalization. Cell 2009; 136: 839-851.
    CrossrefPubMedGoogle Scholar